Neurocrine share price logo

Neurocrine

NASDAQ: NBIX

Large Cap

$156.22

-0.35

(-0.22%)

as on

Neurocrine Stock Performance

as on September 12, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $156.12
    $159.67
    downward going graph

    0.06%

    Downside

    2.21%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $122.14
    $186.12
    downward going graph

    21.82%

    Downside

    19.14%

    Upside

    downward going graph

Neurocrine share price movements today

Previous Close
$156.57
Open
$156.65
Volume
671.2K
Market Cap
$15.8B
Day's Low - High
$156.12 - $159.67
52 Week Low - High
$122.14 - $186.12

Neurocrine Historical Returns

1 Month Return
-5.93 %
3 Month Return
-3.56 %
1 Year Return
+ 9.83 %
3 Year Return
+ 41.98 %
5 Year Return
+ 60.37 %

Neurocrine Stock Fundamentals & Key Indicators

Check Neurocrine market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$15.8B

EPS (TTM)

10.1968

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.31%

PE Ratio (TTM)

22.71

Industry PE ratio

14.49

PEG Ratio

0.3102

EBITDA

913.3M

Revenue (TTM)

3.4B

Profit Margin

20.91%

Return On Equity TTM

22.09%

Neurocrine Stock Valuation

Track how Neurocrine P/E has moved over time to understand its valuation trends.

Neurocrine in the last 5 years

  • Overview

  • Trends

Lowest (17.37x)

March 31, 2026

Industry (14.49x)

September 10, 2026

Today (22.71x)

September 10, 2026

Highest (52.64x)

March 31, 2022

LowHigh

Today’s Price to Earnings Ratio: 22.71x

Neurocrine vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neurocrine with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
BUY$15.8B60.37%22.7120.91%NA
BUY$21.7B141.04%16.7786.14%NA
HOLD$19.4B19.57%-45.8334.83%288.98%
BUY$40.9BNA18.8814.55%134.02%
BUY$31.3B-64.58%12.0670.87%284.12%

Stock Returns calculator for Neurocrine Stock including INR - Dollar returns

The Neurocrine stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Neurocrine investment value today

Current value as on today

₹1,19,711

Returns

₹19,711

(+19.71%)

Returns from Neurocrine Stock

₹10,598 (+10.6%)

Dollar Impact

₹9,113 (+9.11%)

Analyst Recommendation on Neurocrine Stock

Based on 25 analysts

BUY

88.00%

Buy

12.00%

Hold

0.00%

Sell

Based on 25 analysts, 88% of analysts recommend a 'BUY' rating for Neurocrine. Average target price of $211.72

Neurocrine Share Price Target

Get share price movements and forecasts by analysts on Neurocrine.

What analysts predicted

26.21%UPSIDE

Target Price

$211.72

Current Price

$156.22

Analyzed by

25 Analysts

Target

$211.72

Neurocrine target price $211.72, a slight upside of 26.21% compared to current price of $156.22. According to 25 analysts rating.

Indian Investors' Interest in Neurocrine Stock

Search interest for Neurocrine Stock has increased by 32% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:32% versus previous 30 day period

Neurocrine Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
515
590
622
627
572
687
794
805
814
959
Gross Profit
507
581
614
618
563
676
780
787
800
935
Operating Income
99
145
183
142
23
145
239
210
186
153
EBITDA
111
155
191
181
31
166
299
235
193
189
Interest Expense
1
49
-
-
-
-
-
-
-
2
Depreciation
6
7
6
7
7
7
7
7
7
24
Income Before Tax
34
98
190
162
14
159
291
239
246
162
Income Tax Expense
-8
33
60
59
6
52
82
85
48
17
Net Income
43
65
129
103
7
107
209
153
197
144
Net Profit Margin
8.42%
11.01%
20.86%
16.43%
1.38%
15.64%
26.36%
19.08%
24.30%
15.06%

Neurocrine Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
15
161
451
788
1,045
1,133
1,488
1,887
2,355
2,860
Gross Profit
15
160
446
780
1,035
1,119
1,465
1,847
2,321
2,808
Operating Income
-147
-131
36
72
163
102
249
250
570
619
EBITDA
-139
-120
40
85
148
138
264
416
639
666
Interest Expense
-
19
30
32
32
25
7
4
126
-
Depreciation
-
2
4
7
8
10
15
20
27
30
Income Before Tax
-141
-142
21
46
106
101
213
332
486
705
Income Tax Expense
-7
17
0
9
-300
11
59
82
144
226
Net Income
-141
-142
21
37
407
89
154
249
341
478
Net Profit Margin
-940.60%
-88.19%
4.68%
4.69%
38.94%
7.90%
10.38%
13.23%
14.49%
16.73%

Neurocrine Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
65
129
103
7
107
209
153
197
144
Operating Cash Flow
64
158
242
64
102
227
388
145
136
Investing Cash Flow
-28
24
-68
14
-29
-196
-52
-506
-135
Financing Cash Flow
-293
26
-290
-117
-3
45
37
-86
63
Change in Cash
-256
209
-116
-38
69
76
372
-446
64

Neurocrine Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-142
21
37
407
89
154
249
341
478
Operating Cash Flow
-94
101
147
228
256
339
389
595
782
Investing Cash Flow
-251
-242
-211
4
-130
-177
-467
-126
-264
Financing Cash Flow
516
29
32
-157
27
-234
65
-486
-38
Change in Cash
171
-112
-31
74
153
-73
-11
-18
480

Mutual Funds that own Neurocrine Stock

Check out the Mutual Funds with significant holdings in Neurocrine.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.797063%
7925651
Dodge & Cox Funds
4.347465%
4419163
J.P. Morgan Mutual Fund Investment Trust
1.30189%
1323361
JPMorgan Trust II
1.187666%
1207253
Fidelity Concord Street Trust
0.984331%
1000565

Global Institutional Holdings in Neurocrine

Funds
Holdings
iShares
11.95%
Vanguard
8.61%
John A. Gunn
5.49%
SPDR
2.58%
JPMorgan
1.56%

Neurocrine News & Key Events

  • img

    Today's Timeline - 21 July

    Tue, 09:01 PM

    -

    Neurocrine has an Earnings ESP of +40.60% and Zacks Rank #1, with expected significant EPS growth.

    Wed, 01:35 AM

    -

    Neurocrine appoints Samir Siddhanti as Chief Business Officer to lead enterprise growth strategy and oversee business development.

Insights on Neurocrine

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, NBIX stock has moved up by 0.4%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, 572.60M → 958.99M (in $), with an average increase of 9.5% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 65.8% return, outperforming this stock by 55.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 67.3% return, outperforming this stock by 33.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 197.89M → 144.39M (in $), with an average decrease of 27.0% per quarter

About Neurocrine

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
OrganisationNeurocrine
Headquarters6027 Edgewood Bend Court, San Diego, CA, United States, 92130
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Kyle W. Gano Ph.D.
E-voting on sharesClick here to vote

Key Management of Neurocrine

Name

Title

Mr. Lewis Choi

Chief Information Officer

Mr. Kyle W. Gano Ph.D.

President, CEO & Director

Dr. Sanjay Keswani B.Sc., M.D., MBBS

Chief Medical Officer

Dr. Lawrence Steinman BA, M.D., Ph.D.

Co-Founder of Neurocrine

Mr. Aaron Vosburgh

Senior Vice President of Finance & Accounting

Dr. Wylie W. Vale Ph.D.

Co-Founder

Mr. Matthew C. Abernethy CPA

Chief Financial Officer

Dr. Jude Onyia Ph.D.

Chief Scientific Officer

Mr. Eric S. Benevich

Chief Commercial Officer

Dr. Eiry Wyn Roberts M.D.

Strategic Advisor

FAQs

What is Neurocrine share price today?

Neurocrine share price today is $156.22 as on at the close of the market. Neurocrine share today touched a day high of $159.67 and a low of $156.12.

What is the 52 week high and 52 week low for Neurocrine share?

Neurocrine share touched a 52 week high of $186.12 on and a 52 week low of $122.14 on . Neurocrine stock price today i.e. is closed at $156.22,which is 16.06% down from its 52 week high and 27.91% up from its 52 week low.

What is Neurocrine's market capitalisation today?

Neurocrine market capitalisation is $0.02T as on .

How to invest in Neurocrine Stock (NBIX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Neurocrine on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neurocrine Shares that will get you 0.0096 shares as per Neurocrine share price of $156.22 per share as on September 12, 2026 at 8:45 am IST.

What is the minimum amount required to buy Neurocrine Stock (NBIX) from India?

Indian investors can start investing in Neurocrine (NBIX) shares with as little as ₹95.54 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.40 in Neurocrine stock (as per the Rupee-Dollar exchange rate as on ). Based on Neurocrine share’s latest price of $156.22 as on September 12, 2026 at 8:45 am IST, you will get 0.0640 shares of Neurocrine. Learn more about fractional shares .

What are the returns that Neurocrine has given to Indian investors in the last 5 years?

Neurocrine stock has given 60.37% share price returns and 28.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?